Slide 1: Q2 Results Second Quarter of 2022
Q2 RESULTS Second Quarter of 2022
Slide 2: Table of Contents
TABLE OF CONTENTS 01 2Q 2022 RESULTS 02 INCOME STATEMENT AND BALANCE SHEET 03 OUTLOOK FOR 2022 04 RJF SHARE PERFORMANCE
Slide 3: 2Q 2022 Results
RESULTS 01 fet REIGIQJOFRE ~=
Slide 4: Results for Second Quarter of 2022: Sales €132.6M
RESULTS FOR SECOND QUARTER OF 2022 REIG JOFRE grew by 14% in revenue and 6% in EBITDA in the first half of 2022 The sales figure for the first half of 2022 reached 132 million euros, exceeding the same period + 14% of 2021 by 14%. Recovery from the sale of antibiotics and good performance in the F
Slide 5: Revenue by Business Unit
REVENUE BY BUSINESS UNIT PHARMACEUTICAL SPECIALTY CONSUMER TECHNOLOGIES PHARMACARE HEALTHCARE Antibiotics Osteoarticular OTC Injectables / Lyophilizates Dermatology Energy Stress and sleep Weight control €63.4 €37.1 Beauty €32.0 48 % million 28 % million 24 % million +21% +2% +18 % This division g
Slide 6: Sales by Geographical Area
SALES BY GEOGRAPHICAL AREA Rest of Rest of SPAIN EUROPE WORLD 43% 46% 11% 57.6M€ 60.7M€ 14.3M€ Spain European 43% Union + 6% + 30% - 6% 39% Revenue grew in the Spanish market due to a greater consumption of antibiotics as well as good progress in consumer healthcare products: OTC and Forté Pharma
Slide 7: Income Statement & Balance Sheet
INCOME STATEMENT & BALANCE SHEET 02
Slide 8: Income Statement
INCOME STATEMENT 2022 / 2021 Outlook 2Q 2022 thousand euros 30/06/2022 30/06/2021 A significant 14% growth in sales figures, with a 59% gross sales margin, slightly less than the same period in 2021, due to the greater Turnover 132.556 116.115 weight of antibiotics, whose margin is below the avera
Slide 9: Balance Sheet
BALANCE SHEET €4.4 Q2 2022 thousand euros 30/06/2022 30/06/2021 2022 INVESTMENT ASSETS million Goodwill 29.574 29.926 Other intangible assets 74.780 81.128 Property, plant and equipment 91.235 90.939 R&D CAPITALISATION Investments in equity-accounted investees 1.978 1.877 CAPEX 1.7 M Non-current fin
Slide 10: Balance Sheet: Net Financial Debt
BALANCE SHEET 2Q 2022 NET FINANCIAL DEBT Debt|EBITDA thousand euros 30/06/2022 30/06/2021 TOTAL EQUITY 191.062 188.213 69.9 year-end year-end Capital grants 3.040 2.355 2Q22 € million 2Q22 2.5 Provisions 201 287 year-end year-end 69.0 2.5 Financial liabilities with credit institutions 31.685 28.821
Slide 11: Outlook 2022
OUTLOOK 2022 SS fet REIGIQJOFRE ~=
Slide 12: Outlook for 2022
Outlook for REIG JOFRE resumes its strategic growth plan in 2022, in a market context in which the demand for hospital products is clearly recovering and with the operational start-up of the new injectables plant in Barcelona, which has already begun manufacturing its products. 2022 The first six mo
Slide 13: RJF Share Performance
RJF SHARE PERFORMANCE ey REIGQIJOFRE ~=
Slide 14: RJF Share Performance 2022
RJF SHARE PERFORMANCE 2022 MARKET CAP €217M Data as of June 30, 2022 SCRIP DIVIDEND 2022 4,50 • Remuneration 0.04€/ cash or shares Cierre • 97.2% shareholders opt for shares 4,00 31/12/21 • Issuance of 990,533 shares (1.26% capital) 3,50 3,26€ 3,00 AVERAGE DAILY VOLUME 2,50 • Average growth of 5,6%
Slide 15: Links and Further Information
LINKS AND FURTHER INFORMATION LATEST NEWS WEBCAST OF RESULTS SUBSCRIPTION CENTRE www.reigjofre.com/en/news/ www.reigjofre.com/en/investors/webcasts/ www.reigjofre.com/en/news/subscription-center/
Slide 16: Thank you
Q2 Thank you Av. de les Flors 08970 Sant Joan Despí Barcelona, Spain T. +34 93 480 67 10 www.reigjofre.com Investor relations investors@reigjofre.com